Market closed
Kymera Therapeutic/$KYMR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Kymera Therapeutic
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Ticker
$KYMR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
184
Website
KYMR Metrics
BasicAdvanced
$2.7B
Market cap
-
P/E ratio
-$2.41
EPS
2.22
Beta
-
Dividend rate
Price and volume
Market cap
$2.7B
Beta
2.22
52-week high
$51.84
52-week low
$22.11
Average daily volume
461K
Financial strength
Current ratio
8.548
Quick ratio
8.286
Long term debt to equity
8.442
Total debt to equity
9.881
Interest coverage (TTM)
-806.89%
Management effectiveness
Return on assets (TTM)
-15.38%
Return on equity (TTM)
-26.00%
Valuation
Price to revenue (TTM)
33.533
Price to book
3.06
Price to tangible book (TTM)
3.06
Price to free cash flow (TTM)
-19.813
Growth
Revenue change (TTM)
86.92%
Earnings per share change (TTM)
-16.38%
3-year revenue growth (CAGR)
7.57%
3-year earnings per share growth (CAGR)
12.14%
What the Analysts think about KYMR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kymera Therapeutic stock.
KYMR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KYMR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KYMR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kymera Therapeutic stock?
Kymera Therapeutic (KYMR) has a market cap of $2.7B as of December 14, 2024.
What is the P/E ratio for Kymera Therapeutic stock?
The price to earnings (P/E) ratio for Kymera Therapeutic (KYMR) stock is 0 as of December 14, 2024.
Does Kymera Therapeutic stock pay dividends?
No, Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Kymera Therapeutic dividend payment date?
Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Kymera Therapeutic?
Kymera Therapeutic (KYMR) has a beta rating of 2.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.